Cognition Therapeutics (CGTX)

• Market cap: $119M
• 1 day: -1.46%
• 5 days: -5.59%
• 1 month: -16.15%
• 3 months: 0%
• 6 months: 335.77%
• Year to date: 86.7%
• 1 year: 92.5%
• 5 years: -89.43%
• 10 years: -89.43%
• Sector: Healthcare
• Industry: Biotechnology

About: Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of, small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its product candidate CT1812, is an orally delivered, small-molecule antagonist designed to penetrate the blood-brain barrier and bind selectively to the S2R complex.

Employees: 25